- Home
- ISPR vs SLN Comparison
ISPR vs SLN Comparison
Compare ISPR & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ISPR
- SLN
- Stock Information
- Founded
- ISPR 2019
- SLN 1994
- Country
- ISPR United States
- SLN United Kingdom
- Employees
- ISPR N/A
- SLN N/A
- Industry
- ISPR Medicinal Chemicals and Botanical Products
- SLN Biotechnology: Pharmaceutical Preparations
- Sector
- ISPR Health Care
- SLN Health Care
- Exchange
- ISPR Nasdaq
- SLN Nasdaq
- Market Cap
- ISPR 357.4M
- SLN 352.2M
- IPO Year
- ISPR 2023
- SLN N/A
- Fundamental
- Price
- ISPR $5.61
- SLN $6.51
- Analyst Decision
- ISPR Strong Buy
- SLN Strong Buy
- Analyst Count
- ISPR 1
- SLN 4
- Target Price
- ISPR $12.50
- SLN $61.50
- AVG Volume (30 Days)
- ISPR 66.8K
- SLN 761.1K
- Earning Date
- ISPR 11-11-2024
- SLN 11-14-2024
- Dividend Yield
- ISPR N/A
- SLN N/A
- EPS Growth
- ISPR N/A
- SLN N/A
- EPS
- ISPR N/A
- SLN N/A
- Revenue
- ISPR $148,382,357.00
- SLN $21,773,221.00
- Revenue This Year
- ISPR $52.28
- SLN N/A
- Revenue Next Year
- ISPR $42.64
- SLN $104.98
- P/E Ratio
- ISPR N/A
- SLN N/A
- Revenue Growth
- ISPR 12.82
- SLN N/A
- 52 Week Low
- ISPR $5.01
- SLN $5.81
- 52 Week High
- ISPR $13.87
- SLN $27.72
- Technical
- Relative Strength Index (RSI)
- ISPR 45.46
- SLN 27.24
- Support Level
- ISPR $5.47
- SLN $6.06
- Resistance Level
- ISPR $6.38
- SLN $8.88
- Average True Range (ATR)
- ISPR 0.26
- SLN 0.72
- MACD
- ISPR 0.01
- SLN 0.22
- Stochastic Oscillator
- ISPR 50.54
- SLN 22.52
About ISPR Ispire Technology Inc.
Ispire Technology Inc is engaged in the research and development, design, commercialization, sales, marketing, and distribution of branded e-cigarettes and cannabis vaping products. The company sells its cannabis vaping in the United States, Europe, Canada, and South Africa.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risks of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.